Modulation of inflammation by low and high doses of ionizing radiation: Implications for benign and malign diseases

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 230-237

  Frey, Benjamin ^a   Hehlgans, Stephanie ^b   Rödel, Franz ^b   Gaipl, Udo S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Immune biomarkers; Inflammation; Ionizing radiation; Low dose radiation therapy; Tumor associated macrophages; Tumor infiltrating lymphocytes

Indexed keywords

BIOLOGICAL MARKER;

BENIGN TUMOR; CANCER RADIOTHERAPY; DISEASE MARKER; HUMAN; IMMUNOMODULATION; IONIZING RADIATION; LOW ENERGY RADIATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RADIATION RESPONSE; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; CELL DEATH; IMMUNOLOGY; INFLAMMATION; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR MICROENVIRONMENT;

ANIMALS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INFLAMMATION; NEOPLASMS; RADIOTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84941876964     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.010     Document Type: Review

References (123)

1. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
2. Nowarski R., Gagliani N., Huber S., Flavell R.A. Innate immune cells in inflammation and cancer. Cancer Immunol. Res 2013, 1:77-84.
3. Janeway C.A. Janeway's Immunobiology 2008, Garland Science, New York. seventh ed.
4. Ciaccia L. Fundamentals of inflammation. Yale J. Biol. Med 2001, 84:64-65.
5. Tracy R.P. The five cardinal signs of inflammation: calor, dolor, rubor, tumor... and penuria (apologies to Aulus Cornelius Celsus, De medicina, c. A.D. 25). J. Gerontol. A. Biol Sci. Med Sci 2006, 61:1051-1052.
6. Inflammation and Cancer 2014, Springer, Basel. B.B. Aggarwal, B. Sung, S.C. Gupta (Eds.).
7. Schaue D., Kachikwu E.L., McBride W.H. Cytokines in radiobiological responses: a review. Radiat. Res 2012, 178:505-523.
8. Schett G., Elewaut D., McInnes I.B., Dayer J.M., Neurath M.F. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat. Med 2013, 19:822-824.
9. Ahmed M.M., Hodge J.W., Guha C., Bernhard E.J., Vikram B., Coleman C.N. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol. Res 2013, 1:280-284.
10. Schaue D., Micewicz E.D., Ratikan J.A., Xie M.W., Cheng G., McBride W.H. Radiation and inflammation. Semin. Radiat. Oncol 2015, 25:4-10.
11. McQuestion M. Evidence-based skin care management in radiation therapy. Semin. Oncol. Nurs 2006, 22:163-173.
12. Pignol J.P., Olivotto I., Rakovitch E., Gardner S., Sixel K., Beckham W., et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J. Clin. Oncol 2008, 26:2085-2092.
13. Hymes S.R., Strom E.A., Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J. Am. Acad. Dermatol 2006, 54:28-46.
14. Scheithauer H., Belka C., Lauber K., Gaipl U.S. Immunological aspects of radiotherapy. Radiat. Oncol 2014, 9:185.
15. Stone H.B., Peters L.J., Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl Cancer Inst 1979, 63:1229-1235.
16. Formenti S.C. Seminars in radiation oncology. Introduction. Semin. Radiat. Oncol 2015, 25:1-3.
17. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol 2012, 22:33-40.
18. Barcellos-Hoff M.H., Derynck R., Tsang M.L., Weatherbee J.A. Transforming growth factor-beta activation in irradiated murine mammary gland. J. Clin. Invest 1994, 93:892-899.
19. Gaipl U.S. Modulation of the immune system by ionizing irradiation and chemotherapeutic agents - contribution of immune activation and blocking of immune suppression to cancer therapy success. Curr. Med. Chem 2012, 19:1739-1740.
20. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys 2004, 58:862-870.
21. Frey B., Rubner Y., Wunderlich R., Weiss E.M., Pockley A.G., Fietkau R., et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr. Med. Chem 2012, 19:1751-1764.
22. Agassi A.M., Myslicki F.A., Shulman J.M., Rotterman Y., Dosoretz D.E., Fernandez E., et al. The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. Future Oncol 2014, 10:2319-2328.
23. Wada S., Harris T.J., Tryggestad E., Yoshimura K., Zeng J., Yen H.R., et al. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int. J. Radiat. Oncol. Biol. Phys 2013, 87:769-776.
24. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
25. Swann J.B., Vesely M.D., Silva A., Sharkey J., Akira S., Schreiber R.D., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:652-656.
26. Bhardwaj N. Harnessing the immune system to treat cancer. J. Clin. Invest 2007, 117:1130-1136.
27. Kim M.R., Lee J., An Y.S., Jin Y.B., Park I.C., Chung E., et al. TGFbeta1 protects cells from gamma-IR by enhancing the activity of the NHEJ repair pathway. Mol. Cancer Res 2014, 13(2):319-329.
28. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013, 14:e218-e228.
29. Hagler M.A., Hadley T.M., Zhang H., Mehra K., Roos C.M., Schaff H.V., et al. TGF-beta signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc. Res 2013, 99:175-184.
30. Balermpas P., Rodel F., Weiss C., Rodel C., Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014, 3:e27403.
31. Balermpas P., Michel Y., Wagenblast J., Seitz O., Weiss C., Rodel F., et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 2014, 110:501-509.
32. Gooden M.J., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 2011, 105:93-103.
33. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
34. Balermpas P., Rodel F., Liberz R., Oppermann J., Wagenblast J., Ghanaati S., et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br. J. Cancer 2014, 111:1509-1518.
35. Chung F.T., Lee K.Y., Wang C.W., Heh C.C., Chan Y.F., Chen H.W., et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int. J. Cancer 2012, 131:E227-E235.
36. Jensen T.O., Schmidt H., Moller H.J., Hoyer M., Maniecki M.B., Sjoegren P., et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J. Clin. Oncol 2009, 27:3330-3337.
37. Lee C.H., Espinosa I., Vrijaldenhoven S., Subramanian S., Montgomery K.D., Zhu S., et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin. Cancer Res 2008, 14:1423-1430.
38. Lima L., Oliveira D., Tavares A., Amaro T., Cruz R., Oliveira M.J., et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol. Oncol 2014, 32:449-457.
39. Medrek C., Ponten F., Jirstrom K., Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12:306.
40. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med 2010, 362:875-885.
41. Tan K.L., Scott D.W., Hong F., Kahl B.S., Fisher R.I., Bartlett N.L., et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial. Blood 2012, 120:3280-3287.
42. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med 2013, 19:1264-1272.
43. Saied A., Pillarisetty V.G., Katz S.C. Immunotherapy for solid tumors - a review for surgeons. J. Surg. Res 2014, 187:525-535.
44. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov 2013, 12:931-947.
45. Bogdandi E.N., Balogh A., Felgyinszki N., Szatmari T., Persa E., Hildebrandt G., et al. Effects of low-dose radiation on the immune system of mice after total-body irradiation. Radiat. Res 2010, 174:480-489.
46. Nowosielska E.M., Cheda A., Wrembel-Wargocka J., Janiak M.K. Anti-neoplastic and immunostimulatory effects of low-dose X-ray fractions in mice. Int. J. Radiat. Biol 2011, 87:202-212.
47. Yang G., Kong Q., Wang G., Jin H., Zhou L., Yu D., et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother. Radiopharm 2014, 29:428-434.
48. Rosental B., Appel M.Y., Yossef R., Hadad U., Brusilovsky M., Porgador A. The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells. Curr. Med. Chem 2012, 19:1780-1791.
49. Multhoff G., Mizzen L., Winchester C.C., Milner C.M., Wenk S., Eissner G., et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol 1999, 27:1627-1636.
50. Multhoff G., Pockley A.G., Schmid T.E., Schilling D. The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 2015.
51. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol 2013, 10:230-252.
52. Cho D., Kim S.K., Carson W.E. NK cell-based immunotherapy for treating cancer: will it be promising?. Korean J. Hematol 2011, 46:3-5.
53. Scholch S., Rauber C., Tietz A., Rahbari N.N., Bork U., Schmidt T., et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015, 6:4663-4676.
54. Specht H.M., Ahrens N., Blankenstein C., Duell T., Fietkau R., Gaipl U.S., et al. Review article: heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front. Immunol 2015, 6:1-9.
55. Frank S.J., Samelson L.E., Klausner R.D. The structure and signalling functions of the invariant T cell receptor components. Semin. Immunol 1990, 2:89-97.
56. Moretta A., Ciccone E., Pantaleo G., Tambussi G., Bottino C., Melioli G., et al. Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans. Immunol. Rev 1989, 111:145-175.
57. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
58. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med 2004, 10:942-949.
59. Yasuda K., Nirei T., Sunami E., Nagawa H., Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat. Oncol 2011, 6:49.
60. Siddiqui S.A., Frigola X., Bonne-Annee S., Mercader M., Kuntz S.M., Krambeck A.E., et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin. Cancer Res 2007, 13:2075-2081.
61. Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med 2010, 363:24-35.
62. Gupta A., Probst H.C., Vuong V., Landshammer A., Muth S., Yagita H., et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol 2012, 189:558-566.
63. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
64. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
65. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
66. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol 2011, 11:723-737.
67. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol 2013, 229:176-185.
68. Nucera S., Biziato D., De Palma M. The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int. J. Dev. Biol 2011, 55:495-503.
69. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol 2010, 11:889-896.
70. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
71. Russell J.S., Brown J.M. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front. Physiol 2013, 4:157.
72. Ambarus C.A., Krausz S., van Eijk M., Hamann J., Radstake T.R., Reedquist K.A., et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J. Immunol. Methods 2012, 375:196-206.
73. Coates P.J., Rundle J.K., Lorimore S.A., Wright E.G. Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Res 2008, 68:450-456.
74. Iwamoto K.S., McBride W.H. Production of 13-hydroxyoctadecadienoic acid and tumor necrosis factor-alpha by murine peritoneal macrophages in response to irradiation. Radiat. Res 1994, 139:103-108.
75. Nemoto K., Ishihara H., Tanaka I., Suzuki G., Tsuneoka K., Yoshida K., et al. Expression of IL-1 beta mRNA in mice after whole body X-irradiation. J. Radiat. Res. (Tokyo) 1995, 36:125-133.
76. Tsai C.S., Chen F.H., Wang C.C., Huang H.L., Jung S.M., Wu C.J., et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys 2007, 68:499-507.
77. Shiao S.L., Ruffell B., DeNardo D., Faddegon B., Park C.C., Coussens L.M. TH2-polarized CD4+ T cells and macrophages limit efficacy of radiation therapy. Cancer Immunol. Res 2015.
78. Wehrhan F., Buttner-Herold M., Hyckel P., Moebius P., Preidl R., Distel L., et al. Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes - an immunohistochemical study. BMC Cancer 2014, 14:522.
79. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol 2009, 9:162-174.
80. Highfill S.L., Rodriguez P.C., Zhou Q., Goetz C.A., Koehn B.H., Veenstra R., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010, 116:5738-5747.
81. Kodumudi K.N., Weber A., Sarnaik A.A., Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J. Immunol 2012, 189:5147-5154.
82. Klug F., Prakash H., Huber P.E., Seibel T., Bender N., Halama N., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24:589-602.
83. Lauber K., Ernst A., Orth M., Herrmann M., Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front. Oncol 2012, 2:116.
84. Lumniczky K., Safrany G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015, 356:114-125.
85. Cairns R.A., Harris I., McCracken S., Mak T.W. Cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol 2011, 76:299-311.
86. Golden E.B., Apetoh L. Radiotherapy and immunogenic cell death. Semin. Radiat. Oncol 2015, 25:11-17.
87. McBride W.H., Chiang C.S., Olson J.L., Wang C.C., Hong J.H., Pajonk F., et al. A sense of danger from radiation. Radiat. Res 2004, 162:1-19.
88. Rubner Y., Muth C., Strnad A., Derer A., Sieber R., Buslei R., et al. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat. Oncol 2014, 9:89.
89. Galluzzi L., Kepp O., Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013, 2:e26536.
90. Bouquet F., Pal A., Pilones K.A., Demaria S., Hann B., Akhurst R.J., et al. TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res 2011, 17:6754-6765.
91. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) Biological mechanisms of radiation actions at low doses 2012, United Nations, New York.
92. Seegenschmiedt M.H., Micke O. [Radiotherapy of non-malignant diseases. Past, present and future]. Strahlenther. Onkol 2012, 188(Suppl. 3):272-290.
93. Ott O.J., Hertel S., Gaipl U.S., Frey B., Schmidt M., Fietkau R. The Erlangen Dose Optimization Trial for radiotherapy of benign painful shoulder syndrome. Long-term results. Strahlenther. Onkol 2014, 190:394-398.
94. Rodel F., Frey B., Manda K., Hildebrandt G., Hehlgans S., Keilholz L., et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front. Oncol 2012, 2:120.
95. Leer J.W., van Houtte P., Seegenschmiedt H. Radiotherapy of non-malignant disorders: where do we stand?. Radiother. Oncol 2007, 83:175-177.
96. Marples B., Collis S.J. Low-dose hyper-radiosensitivity: past, present, and future. Int. J. Radiat. Oncol. Biol. Phys 2008, 70:1310-1318.
97. Marples B., Wouters B.G., Collis S.J., Chalmers A.J., Joiner M.C. Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells. Radiat. Res 2004, 161:247-255.
98. Rodel F., Frey B., Gaipl U., Keilholz L., Fournier C., Manda K., et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr. Med. Chem 2012, 19:1741-1750.
99. Unanue E.R. Secretory function of mononuclear phagocytes: a review. Am. J. Pathol 1976, 83:396-418.
100. Unanue E.R., Beller D.I., Calderon J., Kiely J.M., Stadecker M.J. Regulation of immunity and inflammation by mediators from macrophages. Am. J. Pathol 1976, 85:465-478.
101. Valledor A.F., Comalada M., Santamaria-Babi L.F., Lloberas J., Celada A. Macrophage proinflammatory activation and deactivation: a question of balance. Adv. Immunol 2010, 108:1-20.
102. Hildebrandt G., Radlingmayr A., Rosenthal S., Rothe R., Jahns J., Hindemith M., et al. Low-dose radiotherapy (LD-RT) and the modulation of iNOS expression in adjuvant-induced arthritis in rats. Int. J. Radiat. Biol 2003, 79:993-1001.
103. Schaue D., Jahns J., Hildebrandt G., Trott K.R. Radiation treatment of acute inflammation in mice. Int. J. Radiat. Biol 2005, 81:657-667.
104. Schaue D., Marples B., Trott K.R. The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages. Int. J. Radiat. Biol 2002, 78:567-576.
105. Rodel F., Hantschel M., Hildebrandt G., Schultze-Mosgau S., Rodel C., Herrmann M., et al. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int. J. Radiat. Biol 2004, 80:115-123.
106. Rodel F., Keilholz L., Herrmann M., Weiss C., Frey B., Voll R., et al. Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. Autoimmunity 2009, 42:343-345.
107. Rodel F., Schaller U., Schultze-Mosgau S., Beuscher H.U., Keilholz L., Herrmann M., et al. The induction of TGF-beta(1) and NF-kappaB parallels a biphasic time course of leukocyte/endothelial cell adhesion following low-dose X-irradiation. Strahlenther. Onkol 2004, 180:194-200.
108. Lodermann B., Wunderlich R., Frey S., Schorn C., Stangl S., Rodel F., et al. Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int. J. Radiat. Biol 2012, 88:727-734.
109. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol 2009, 1:a001651.
110. Wunderlich R., Ernst A., Rodel F., Fietkau R., Ott O., Lauber K., et al. Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin. Exp. Immunol 2015, 179:50-61.
111. Rodel F., Frey B., Capalbo G., Gaipl U., Keilholz L., Voll R., et al. Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. Radiother. Oncol 2010, 97:346-351.
112. Large M., Reichert S., Hehlgans S., Fournier C., Rodel C., Rodel F. A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. Radiat. Oncol 2014, 9:80.
113. Ott O.J., Hertel S., Gaipl U.S., Frey B., Schmidt M., Fietkau R. The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Strahlenther. Onkol 2014, 190:293-297.
114. Ott O.J., Jeremias C., Gaipl U.S., Frey B., Schmidt M., Fietkau R. Radiotherapy for benign calcaneodynia: long-term results of the Erlangen Dose Optimization (EDO) trial. Strahlenther. Onkol 2014, 190:671-675.
115. Deloch L., Derer A., Ruhle P.F., Ott O., Fietkau R., Frey B., et al. Locally restricted low-dose irradiation of human TNF-alpha transgenic mice with 0.5 Gy reduces bone-loss and inflammation in vivo. Strahlenther. Onkol 2014, 190:92.
116. Figueiredo N., Chora A., Raquel H., Pejanovic N., Pereira P., Hartleben B., et al. Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity 2013, 39:874-884.
117. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
118. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
119. Heilmann H.P. [History of German radiation oncology]. Strahlenther. Onkol 2012, 188(Suppl. 3):220-226.
120. Barcellos-Hoff M.H., Cordes N. Radiation therapy and the microenvironment. Int. J. Radiat. Biol 2007, 83:723-725.
121. Thompson R.F., Maity A. Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv. Exp. Med. Biol 2014, 772:147-165.
122. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol 2002, 3:991-998.
123. Rubner Y., Wunderlich R., Ruhle P.F., Kulzer L., Werthmoller N., Frey B., et al. How does ionizing irradiation contribute to the induction of anti-tumor immunity?. Front. Oncol 2012, 2:75.